Article
Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Sept 2022
Bazzell Brian G, Marini Bernard L, Benitez Lydia L, Bixby Dale, Burke Patrick, Pettit Kristen, Perissinotti Anthony J
Abstract excerpt
BACKGROUND: Patients diagnosed with acute myeloid leukemia with a FLT3 mutation (FLT3+ AML) have historically had poor outcomes. While the addition of the FLT3 inhibitors to induction therapy has been shown to improve survival outcomes in FLT3+ AML, interactions and overlapping toxicities between FLT3 inhibitors and standard of care medications used during induction therapy (e.g. azole antifungals,...
Topics
- Azoles
- Cohort Studies
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- Retrospective Studies
- fms-Like Tyrosine Kinase 3